EMA Medicine safety communications
Remsima: new contraindication
Published by European Medicines Agency: · Ref. X-149
Summary
New contraindication
Medicine
Remsima
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): infliximab
- Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid
- ATC code: L04AB02
Measures and alternatives
- Regulatory outcome: Variation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗